Janus Kinase Inhibitor
Litfulo becomes first FDA-approved treatment for adolescents with severe alopecia
The FDA has approved Litfulo, a once-daily oral treatment, for the treatment of severe alopecia in individuals aged 12 years and older, Pfizer announced in a press release.
More JAK inhibitors ‘coming down the pike’ despite poor understanding of mechanism
The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.
VIDEO: Reduce JAK inhibitors 'cautiously and slowly' in patients with alopecia areata
NEW ORLEANS — In this Healio video exclusive, Ronda S. Farah, MD, discusses how reducing Janus kinase inhibitor dosages in patients with alopecia areata should be completed safely.
‘No evidence’ of increased short-term cancer risk for JAK inhibitors vs. TNF inhibitors
Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.
VIDEO: 'Super exciting' results of second phase 3 deuruxolitinib trial
NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses highlights from the American Academy of Dermatology Annual Meeting, including results from the second phase 3 trial of deuruxolitinib.
Patients with lichen planus show improvement with baracitinib
NEW ORLEANS — A first-in-human study found patients with lichen planus treated with the Janus kinase inhibitor baracitinib achieved almost total improvement, according to a presenter at the American Academy of Dermatology Annual Meeting.
VIDEO: Importance of selecting JAK inhibitors based on individual patient
VIDEO: Cardiovascular concerns tied to JAK inhibitor impacts patients, providers
VIDEO: Using JAK inhibitors in combination with conventional synthetic DMARDs